Drug Type Gene therapy |
Synonyms Angiogenic-gene-therapy(ID-Pharma), Recombinant SeV-hFGF2/dF, SeV-hFGF2/dF + [8] |
Target |
Mechanism FGF2 gene transference, Angiogenesis inducers |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Occlusion of artery | NDA/BLA | CN | 10 Sep 2018 | |
Chronic Limb-Threatening Ischemia | NDA/BLA | CN | 05 Sep 2018 | |
Peripheral arterial occlusive disease | NDA/BLA | CN | 05 Sep 2018 | |
Intermittent Claudication | Phase 2 | JP | 01 Oct 2014 | |
Peripheral Arterial Disease | Phase 2 | JP | 01 Oct 2014 | |
Perioperative ischaemia | Phase 2 | - | - | |
Perioperative ischaemia | Phase 2 | - | - |
Phase 1/2 | 27 | rvzviubusm(lburzoxmdi) = bqauudiabe sstkmmqoxq (dkdcjkqebw ) View more | Positive | 22 Apr 2019 |